PB-223 is an innovative mAb developed through immune engineering from the chimeric IgG1 NEO-102 (Ensituximab). It targets a unique core 2 O-glycan (variant of MUC5AC), Preclinical and clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback